Future Prospects – What Lies Ahead for Precision Oncology?

Omico’s Cancer Meets its Match podcast concludes its series with a forward-looking episode titled Future Prospects – What Lies Ahead?, offering expert insights into the evolving landscape of genomic profiling and precision oncology.

This episode features Professor David Thomas, Chief Science and Strategy Officer at Omico, and Christine Cockburn, Chief Executive Officer at Rare Cancers Australia, who reflect on the current state of genomic medicine in Australia, the systemic changes needed to expand its use, and the transformative potential of precision oncology over the next 5 to 10 years.

Together, they highlight the critical importance of data integration, national infrastructure, equity of access, and sustained investment in research and policy to ensure genomic technologies can reach more Australians. Their perspectives underscore the alignment between innovation in science and the advocacy needed to turn potential into practice.

Listen to the full podcast here: Omico’s Cancer Meets its Match

We extend our sincere thanks to Omico, Professor David Thomas, and Christine Cockburn for their thought leadership and commitment to advancing genomics in healthcare. Follow InGeNA for the latest developments in genomics innovation and precision medicine across Australia.